|
1.
|
|
11 p, 618.2 KB |
Characterization of the endotheliopathy, innate-immune activation and hemostatic imbalance underlying CAR-T cell toxicities : Laboratory tools for an early and differential diagnosis
/
Moreno-Castaño, Ana Belén (Hospital Clínic i Provincial de Barcelona) ;
Fernández, Sara (Hospital Clínic i Provincial de Barcelona) ;
Ventosa, Helena (Hospital Clínic i Provincial de Barcelona) ;
Palomo, Marta (Hospital Clínic i Provincial de Barcelona) ;
Martinez-Sanchez, Julia (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Ramos, Alex (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Ortiz-Maldonado, Valentín (Hospital Clínic i Provincial de Barcelona) ;
Delgado, Julio (Hospital Clínic i Provincial de Barcelona) ;
Fernández De Larrea, Carlos (Hospital Clínic i Provincial de Barcelona) ;
Urbano-Ispizua, Alvaro (Hospital Clínic i Provincial de Barcelona) ;
Penack, Olaf (Charité Universitätsmedizin Berlin, Germany) ;
Nicolás, J.M. (Hospital Clínic i Provincial de Barcelona) ;
Téllez, Adrian (Hospital Clínic i Provincial de Barcelona) ;
Escolar, Gines (Hospital Clínic i Provincial de Barcelona) ;
Carreras, Enric (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Fernández-Avilés, Francesc (Hospital Clínic i Provincial de Barcelona) ;
Castro Rebollo, Pedro (Hospital Clínic i Provincial de Barcelona) ;
Diaz-Ricart, Maribel (Hospital Clínic i Provincial de Barcelona)
Background Chimeric antigen receptor (CAR)-T cell-based immunotherapy constitutes a revolutionary advance for treatment of relapsed/refractory hematological malignancies. Nevertheless, cytokine release and immune effector cell-associated neurotoxicity syndromes are life-threatening toxicities in which the endothelium could be a pathophysiological substrate. [...]
2023 -  10.1136/jitc-2022-006365
Journal for immunotherapy of cancer, Vol. 11 Núm. 4 (april 2023)
|
|
|
2.
|
|
11 p, 529.4 KB |
Nivolumab and sunitinib combination in advanced soft tissue sarcomas : A multicenter, single-arm, phase Ib/II trial
/
Martin-Broto, J. (Universidad de Sevilla) ;
Hindi, Nadia (Universidad de Sevilla) ;
Grignani, G. (Candiolo Cancer Institute) ;
Martinez-Trufero, J. (Hospital Universitario Miguel Servet (Saragossa)) ;
Redondo, A. (Hospital Universitario La Paz (Madrid)) ;
Valverde, Claudia (Vall d'Hebron Institut d'Oncologia) ;
Stacchiotti, S. (Istituto Nazionale Tumori) ;
López Pousa, Antonio (Institut d'Investigació Biomèdica Sant Pau) ;
D'Ambrosio, L. (Candiolo Cancer Institute) ;
Gutierrez, A. (Hospital Universitari Son Espases (Palma de Mallorca, Balears)) ;
Perez-Vega, H. (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Encinas-Tobajas, V. (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
De Álava, Enrique (Universidad de Sevilla) ;
Collini, Paola (Istituto Nazionale Tumori) ;
Peña-Chilet, M. (Hospital Virgen Del Rocio) ;
Dopazo, J. (Hospital Virgen Del Rocío) ;
Carrasco-Garcia, I. (Universidad de Sevilla) ;
Lopez-Alvarez, M. (Universidad de Sevilla) ;
Moura, D.S. (Universidad de Sevilla) ;
Lopez-Martin, Jose A (Instituto de Investigación Sanitaria Hospital 12 de Octubre (i+12)) ;
Universitat Autònoma de Barcelona
Sarcomas exhibit low expression of factors related to immune response, which could explain the modest activity of PD-1 inhibitors. A potential strategy to convert a cold into an inflamed microenvironment lies on a combination therapy. [...]
2020 - 10.1136/jitc-2020-001561
Journal for immunotherapy of cancer, Vol. 8 Núm. 2 (17 2020) , p. e001561
|
|
|
3.
|
|
13 p, 7.8 MB |
Systemic cellular viroimmunotherapy for canine high-grade gliomas
/
Cloquell, Ana (Universidad Alfonso X El Sabio) ;
Mateo Pampliega, Isidro (Hospital Veterinario VETSIA) ;
Gambera, Stefano (Spanish National Centre for Cardiovascular Research (CNIC)) ;
Pumarola i Batlle, Martí (Universitat Autònoma de Barcelona. Departament de Medicina i Cirurgia Animals) ;
Alemany Bonastre, Ramon (Institut Català d'Oncologia) ;
Garcia-Castro, Javier (Instituto de Salud Carlos III) ;
Perisé-Barrios, Ana Judith (Universidad Alfonso X El Sabio)
Oncolytic viruses constitute a growing field of interest, both in human and veterinary oncology, given that they are particularly helpful for treating non-surgical tumors and disseminated cancer, such as high-grade gliomas. [...]
2022 - 10.1136/jitc-2022-005669
Journal for immunotherapy of cancer, Vol. 10 (december 2022)
|
|
|
4.
|
|
14 p, 3.3 MB |
A Phase I-II multicenter trial with Avelumab plus autologous dendritic cell vaccine in pre-treated mismatch repair-proficient (MSS) metastatic colorectal cancer patients; GEMCAD 1602 study
/
Español-Rego, Marta (Hospital Clínic i Provincial de Barcelona) ;
Fernández-Martos, Carlos (Instituto Valenciano de Oncología. Medical Oncology Department) ;
Elez, Elena (Vall d'Hebron Institut d'Oncologia) ;
Foguet, Carles (Universitat de Barcelona. Department of Biochemistry and Molecular Medicine) ;
Pedrosa, Leire (Hospital Clínic i Provincial de Barcelona) ;
Rodríguez, Nuria (Centro de Investigación Biomédica en Red de Cáncer) ;
Ruiz-Casado, Ana (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ;
Pineda, Estela (Hospital Clínic i Provincial de Barcelona) ;
Cid, Joan (Hospital Clínic i Provincial de Barcelona) ;
Cabezón, Raquel (Hospital Clínic i Provincial de Barcelona) ;
Oliveres, Helena (Hospital Clínic i Provincial de Barcelona) ;
Lozano, Miquel (Hospital Clínic i Provincial de Barcelona) ;
Ginés, Angels (Instituto Nacional de La Salud Carlos III. Networked Center for Hepatic and Digestive Diseases) ;
García-Criado, Angeles (Hospital Clínic i Provincial de Barcelona) ;
Ayuso, Juan Ramon (Hospital Clínic i Provincial de Barcelona) ;
Pagés, Mario (Hospital Clínic i Provincial de Barcelona) ;
Cuatrecasas, Miriam (Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas) ;
Torres Benítez, Ferran (Universitat Autònoma de Barcelona. Unitat de Bioestadística) ;
Thomson, Timothy (Universidad Peruana Cayetano Heredia) ;
Cascante, Marta (Instituto Nacional de La Salud Carlos III) ;
Benítez Ribas, Daniel (Hospital Clínic i Provincial de Barcelona) ;
Torres Benítez, Ferran (Instituto Nacional de La Salud Carlos III)
Immune check-point blockade (ICB) has shown clinical benefit in mismatch repair-deficient/microsatellite instability high metastatic colorectal cancer (mCRC) but not in mismatch repair-proficient/microsatellite stable patients. [...]
2022 - 10.1007/s00262-022-03283-5
Cancer Immunology, Immunotherapy, Vol. 72 (september 2022) , p. 827-840
|
|
|
5.
|
|
7 p, 657.6 KB |
Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinations
/
Cortellini, Alessio (Imperial College London) ;
Ricciuti, Biagio (Lowe Center for Thoracic Oncology. Dana Farber Cancer Institute) ;
Vaz, Victor R. (Lowe Center for Thoracic Oncology. Dana Farber Cancer Institute) ;
Soldato, Davide (Cancer Medicine Department. Gustave Roussy) ;
Alessi, Joao V. (Lowe Center for Thoracic Oncology. Dana Farber Cancer Institute) ;
Dall'olio, Filippo G. (Cancer Medicine Department. Gustave Roussy) ;
Banna, Giuseppe L. (Candiolo Cancer Institute. FPO-IRCCS) ;
Muthuramalingam, Sethupathi (Oncology Department. United Lincolnshire Hospital NHS Trust) ;
Chan, Samuel (Oncology Department. Queen Alexandra University Hospital. Portsmouth Hospitals NHS Trust) ;
Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ;
Piedra, Aida (Institut d'Investigació Biomèdica Sant Pau) ;
Lamberti, Giuseppe (Department of Experimental Diagnostic and Specialty Medicine. S. Orsola-Malpighi University Hospital. Alma Mater Studiorum University of Bologna) ;
Andrini, Elisa (Department of Experimental Diagnostic and Specialty Medicine. S. Orsola-Malpighi University Hospital. Alma Mater Studiorum University of Bologna) ;
Addeo, Alfredo (Medical Oncology. University Hospital of Geneva) ;
Friedlaender, Alex (Medical Oncology. University Hospital of Geneva) ;
Facchinetti, Francesco (Université Paris-Saclay) ;
Gorriá, Teresa (Hospital Clínic i Provincial de Barcelona) ;
Mezquita, Laura (Hospital Clínic i Provincial de Barcelona) ;
Hoton, Delphine (Department of Pathology. Cliniques Universitaires Saint-Luc) ;
Valerie, Lacroix (Department of Cardiovascular and Thoracic Surgery. IREC. Cliniques Universitaires Saint-Luc) ;
Nana, Frank Aboubakar (Institut de Recherche Expérimentale et Clinique (IREC). Pôle de Pneumologie. ORL et Dermatologie (PNEU). Université Catholique de Louvain (UCLouvain)) ;
Artingstall, James (Bristol Haematology and Oncology Centre) ;
Comins, Charles (Bristol Haematology and Oncology Centre) ;
Di Maio, Massimo (Department of Oncology. University of Turin and Mauriziano Hospital) ;
Caglio, Andrea (Department of Oncology. University of Turin and Mauriziano Hospital) ;
Cave, Judith (Department of Medical Oncology. University Hospital Southampton NHS Foundation Trust) ;
McKenzie, Hayley (Department of Medical Oncology. University Hospital Southampton NHS Foundation Trust) ;
Newsom-Davis, Thomas (Department of Oncology. National Centre for HIV Malignancies. Chelsea and Westminster Hospital) ;
Evans, Joanne S. (Imperial College London) ;
Tiseo, Marcello (Medical Oncology Unit. University Hospital of Parma) ;
D'Alessio, Antonio (Department of Biomedical Sciences. Humanitas University) ;
Fulgenzi, Claudia A.M. (Department of Medical Oncology. University Campus Bio-Medico) ;
Besse, Benjamin (School of Medicine. University Paris-Saclay) ;
Awad, Mark M. (Lowe Center for Thoracic Oncology. Dana Farber Cancer Institute) ;
Pinato, David J. (Division of Oncology. Department of Translational Medicine. University of Piemonte Orientale)
Introduction It has been recognized that increasing body mass index (BMI) is associated with improved outcome from immune checkpoint inhibitors (ICIs) in patients with various malignancies including non-small cell lung cancer (NSCLC). [...]
2022 - 10.1136/jitc-2021-004374
Journal for immunotherapy of cancer, Vol. 10 Núm. 2 (February 2022) , p. e004374
|
|
|
6.
|
|
14 p, 4.8 MB |
Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy
/
Casarrubios, Marta (Instituto de Investigación Sanitaria Puerta de Hierro - Segovia de Arana) ;
Provencio, Mariano (Instituto de Investigación Sanitaria Puerta de Hierro - Segovia de Arana) ;
Nadal, Ernest (Institut d'Investigació Biomèdica de Bellvitge) ;
Insa, Amelia (Hospital Clínic Universitari (València)) ;
Del Rosario García-Campelo, María (Complejo Hospitalario Universitario de A Coruña) ;
Lázaro, Martín (Hospital Universitario de Vigo) ;
Dómine, Manuel (Hospital Universitario Fundación Jiménez Díaz) ;
Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ;
Rodríguez-Abreu, Delvys (Hospital Universitario Insular de Gran Canaria) ;
Martinez-Marti, Alex (Vall d'Hebron Institut d'Oncologia) ;
de Castro, Javier (Hospital Universitario La Paz (Madrid)) ;
Cobo, Manuel (Instituto de Investigación Biomédica de Málaga) ;
López-Vivanco, Guillermo (Hospital Universitario de Cruces (Barakaldo, País Basc)) ;
Del Barco Morillo, Edel (Hospital Universitario de Salamanca) ;
Bernabé, Reyes (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Viñolas, Nuria (Hospital Clínic i Provincial de Barcelona) ;
Barneto Aranda, Isidoro (Hospital Universitario Reina Sofía (Còrdova, Espanya)) ;
Massuti, Bartomeu (Hospital General Universitario de Alicante (Alacant, País Valencià)) ;
Sierra-Rodero, Belén (Instituto de Investigación Sanitaria Puerta de Hierro - Segovia de Arana) ;
Martinez-Toledo, Cristina (Instituto de Investigación Sanitaria Puerta de Hierro - Segovia de Arana) ;
Fernández-Miranda, Ismael (Instituto de Investigación Sanitaria Puerta de Hierro - Segovia de Arana) ;
Serna-Blanco, Roberto (Instituto de Investigación Sanitaria Puerta de Hierro - Segovia de Arana) ;
Romero, Atocha (Instituto de Investigación Sanitaria Puerta de Hierro - Segovia de Arana) ;
Calvo, Virginia (Instituto de Investigación Sanitaria Puerta de Hierro - Segovia de Arana) ;
Cruz-Bermúdez, Alberto (Instituto de Investigación Sanitaria Puerta de Hierro - Segovia de Arana)
Background Neoadjuvant chemoimmunotherapy for non-small cell lung cancer (NSCLC) has improved pathological responses and survival rates compared with chemotherapy alone, leading to Food and Drug Administration (FDA) approval of nivolumab plus chemotherapy for resectable stage IB-IIIA NSCLC (AJCC 7th edition) without ALK or EGFR alterations. [...]
2022 - 10.1136/jitc-2022-005320
Journal for immunotherapy of cancer, Vol. 10 Núm. 9 (september 2022) , p. e005320
|
|
|
7.
|
|
13 p, 2.9 MB |
Clinical and molecular parameters associated to pneumonitis development in non-small-cell lung cancer patients receiving chemoimmunotherapy from NADIM trial
/
Sierra-Rodero, Belén (Instituto de Investigación Sanitaria Puerta de Hierro - Segovia de Arana) ;
Cruz-Bermúdez, Alberto (Instituto de Investigación Sanitaria Puerta de Hierro - Segovia de Arana) ;
Nadal, Ernest (Institut d'Investigació Biomèdica de Bellvitge) ;
Garitaonaindiá, Yago (Instituto de Investigación Sanitaria Puerta de Hierro - Segovia de Arana) ;
Insa, Amelia (INCLIVA. Valencia) ;
Mosquera, Joaquín (Complejo Hospitalario Universitario de A Coruña) ;
Casal-Rubio, Joaquín (Hospital Universitario de Vigo) ;
Dómine, Manuel (Hospital Universitario Fundación Jiménez Díaz) ;
Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ;
Rodríguez-Abreu, Delvys (Hospital Universitario Insular de Gran Canaria) ;
Martinez-Marti, Alex (Vall d'Hebron Institut d'Oncologia) ;
de Castro, Javier (Hospital Universitario La Paz (Madrid)) ;
Cobo, Manuel (Hospital Regional Universitario de Málaga) ;
López Vivanco, Guillermo (Hospital Universitario de Cruces (Barakaldo, País Basc)) ;
Del Barco Morillo, Edel (Hospital Universitario de Salamanca) ;
Bernabé, Reyes (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Viñolas, Nuria (Hospital Clínic i Provincial de Barcelona) ;
Barneto Aranda, Isidoro (Hospital Universitario Reina Sofía (Còrdova, Espanya)) ;
Viteri, Santiago (Instituto Oncológico Dr. Rosell. Hospital Universitario Quiron Dexeus) ;
Massuti, Bartomeu (Hospital General Universitario de Alicante (Alacant, País Valencià)) ;
Laza-Briviesca, Raquel (Instituto de Investigación Sanitaria Puerta de Hierro - Segovia de Arana) ;
Casarrubios, Marta (Instituto de Investigación Sanitaria Puerta de Hierro - Segovia de Arana) ;
Garciá-Grande, Aránzazu (Instituto de Investigación Sanitaria Puerta de Hierro - Segovia de Arana) ;
Romero, Atocha (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ;
Franco, Fernando (Instituto de Investigación Sanitaria Puerta de Hierro - Segovia de Arana) ;
Provencio, Mariano (Instituto de Investigación Sanitaria Puerta de Hierro - Segovia de Arana)
Background Pneumonitis (Pn) is one of the main immune-related adverse effects, having a special importance in lung cancer, since they share affected tissue. Despite its clinical relevance, Pn development remains an unpredictable treatment adverse effect, whose mechanisms are mainly unknown, being even more obscure when it is associated to chemoimmunotherapy. [...]
2021 - 10.1136/jitc-2021-002804
Journal for immunotherapy of cancer, Vol. 9 Núm. 8 (august 2021) , p. e002804
|
|
|
8.
|
|
13 p, 6.9 MB |
Generation and proof-of-concept for allogeneic CD123 CAR-Delta One T (DOT) cells in acute myeloid leukemia
/
Sánchez Martínez, Diego (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Tirado, Nestor (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Mensurado, Sofía (Universidade de Lisboa) ;
Martínez Moreno, Alba (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Romecín, Paola Alejandra (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Gutiérrez-Agüera, Francisco (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Correia, Daniel V. (Universidade de Lisboa) ;
Silva-Santos, Bruno (Universidade de Lisboa) ;
Menéndez Bujan, Pablo (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
Background Chimeric antigen receptor (CAR)-T cells have emerged as a breakthrough treatment for relapse/refractory hematological tumors, showing impressive complete remission rates. However, around 50% of the patients relapse before 1-year post-treatment. [...]
2022 - 10.1136/jitc-2022-005400
Journal for immunotherapy of cancer, Vol. 10 Núm. 9 (september 2022) , p. e005400
|
|
|
9.
|
|
9 p, 1.7 MB |
Factors associated with the clinical outcome of patients with relapsed/refractory CD19 + acute lymphoblastic leukemia treated with ARI-0001 CART19-cell therapy
/
Ortiz-Maldonado, Valentín (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Rives, Susana (Institut de Recerca Pediàtrica Sant Joan de Déu) ;
Español-Rego, Martas (Hospital Sant Joan de Déu (Manresa)) ;
Montoro, Mercedes (Hospital Clínic i Provincial de Barcelona) ;
Magnano, Laura (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Giné, Eva (Centro de Investigación Biomédica en Red de Cáncer) ;
Pascal, Mariona (Hospital Clínic i Provincial de Barcelona) ;
Díaz-Beyá, Marina (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Castella, Mariona (Centro de Investigación Biomédica en Red de Enfermedades Raras) ;
Faura, Anna (Hospital Sant Joan de Déu (Manresa)) ;
Rodríguez-Lobato, Luis Gerardo (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Oliver-Caldés, Aina (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Martínez-Roca, Alexandra (Hospital Clínic i Provincial de Barcelona) ;
Rovira Argelagués, Montserrat (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
González-Navarro, E. Azucena (Hospital Clínic i Provincial de Barcelona) ;
Ortega, Juan Ramón (Hospital Clínic i Provincial de Barcelona) ;
Cid, Joan (Hospital Clínic i Provincial de Barcelona) ;
Lozano, Miquel (Universitat de Barcelona) ;
Garcia-Rey, Enric (Banc de Sang i Teixits) ;
Fernández, Sara (Hospital Clínic i Provincial de Barcelona) ;
Castro, Pedro (Hospital Clínic i Provincial de Barcelona) ;
Jordán García, Iolanda (Hospital Sant Joan de Déu (Manresa)) ;
Villamor, Neus (Hospital Clínic i Provincial de Barcelona) ;
Aymerich, Marta (Hospital Clínic i Provincial de Barcelona) ;
Torrebadell, Montserrat (Hospital Sant Joan de Déu (Manresa)) ;
Deyà-Martínez, Ángela (Hospital Sant Joan de Déu (Manresa)) ;
Fernandez de Larrea Rodriguez, Carlos (Universitat de Barcelona) ;
Benítez Ribas, Daniel (Hospital Clínic i Provincial de Barcelona) ;
Trias, Esteve (Hospital Clínic i Provincial de Barcelona) ;
Varea, Sara (Hospital Clínic i Provincial de Barcelona) ;
Calvo, Gonzalo (Hospital Clínic i Provincial de Barcelona) ;
Esteve Reyner, Jordi (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Urbano-Ispizua, Álvaro (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Juan, Manel (Hospital Sant Joan de Déu (Barcelona, Catalunya)) ;
Delgado, Julio (Universitat de Barcelona) ;
Universitat Autònoma de Barcelona
2021 - 10.1136/jitc-2021-003644
Journal for immunotherapy of cancer, Vol. 9 Núm. 12 (january 2021) , p. e003644
|
|
|
10.
|
|
21 p, 12.7 MB |
NK cells enhance CAR-T cell antitumor efficacy by enhancing immune/tumor cells cluster formation and improving CAR-T cell fitness
/
Bachiller, Mireia (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Pérez-Amill, Lorena (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Battram, Anthony M (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Carné, Sebastian Ciro (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Najjar, Amer (The University of Texas MD Anderson Cancer Center) ;
Verhoeyen, Els (Université Côte d'Azur) ;
Juan, Manel (Universitat de Barcelona. Departament de Medicina) ;
Urbano-Ispizua, Alvaro (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Martín-Antonio, B (Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz) ;
Universitat Autònoma de Barcelona
Background Chimeric antigen receptor (CAR)-T cell immunotherapy has modified the concept of treatment in hematological malignancies. In comparison with pediatric patients, where responses are maintained over many years, older patients, such as those with non-Hodgkin's lymphoma (NHL) and multiple myeloma (MM), present lower persistence of CAR-T cells that might be due to decreased fitness of T cells acquired with aging. [...]
2021 - 10.1136/jitc-2021-002866
Journal for immunotherapy of cancer, Vol. 9 Núm. 8 (25 2021) , p. 2866
|
|
visitante ::
identificación
alerta personal vía correo electrónico o subscríbase al 
canal RSS.
